Q3 Earnings Forecast for VolitionRX Issued By Zacks Research

VolitionRX Limited (NYSEAMERICAN:VNRX) – Zacks Research increased their Q3 2026 earnings per share estimates for shares of VolitionRX in a research report issued on Monday, September 14th. Zacks Research analyst S. Ralston now forecasts that the medical research company will post earnings per share of ($0.42) for the quarter, up from their previous estimate of ($0.78). The consensus estimate for VolitionRX’s current full-year earnings is ($2.36) per share. Zacks Research also issued estimates for VolitionRX’s Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.95) EPS.

Several other analysts have also weighed in on VNRX. Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark reissued a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, VolitionRX currently has a consensus rating of “Hold” and an average target price of $28.00.

VolitionRX Stock Performance

Shares of VNRX opened at $0.27 on Thursday. The firm has a market cap of $3.75 million, a PE ratio of -0.07 and a beta of 1.10. VolitionRX has a 52-week low of $0.27 and a 52-week high of $14.80. The business’s 50 day moving average price is $0.68 and its two-hundred day moving average price is $2.01.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.